6. Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in
malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer
Discov. 2015;5:316–31.
7. Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. Characteristics and
treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476
individuals in Germany. J Cancer Res Clin Oncol. 2016;142:2041–9.
8. Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, et al. Epidemiology,
outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a
multicenter study on 446 patients. Hematol Oncol. 2018, PMID: 29624703.
9. Impfkommission Sn. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut.
Epid Bull. 2019:313–64.
10. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia
chromosome-negative classical myeloproliferative neoplasms: revised management
recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.
11. European Medicines Agency (EMA) CfMPfHUC. Asessment report: Jakavi. EMA; 2015.
EMA/139813/2015.
12. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for
anti-infective prophylaxis? Blood. 2013;122:3843–4.
13. Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J, et al. JAK1/2
inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J
Haematol. 2015;169:824–33.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES